Enhanced Hypertonic Pharmaceutical Compositions for Ototoxicity Protection

The present inventive concept provides improved hypertonic pharmaceutical compositions and delivery methods for protecting against platinum-induced ototoxicity, enhancing the safety and efficacy of chemotherapy treatments.

Platinum-based antineoplastic agents are widely used to treat cancers and tumors, but they induce hearing loss in patients. The original patent disclosed hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent, but these compositions have limitations in terms of delivery and bioavailability. The present inventive concept addresses these limitations by providing improved compositions and delivery methods that enhance the bioavailability and efficacy of the chemoprotectant agent.

The inventive concept comprises a system for delivering a hypertonic pharmaceutical composition to a subject's round window, a method for treating platinum-induced ototoxicity using a hypertonic pharmaceutical composition with a tonicity agent, a composition with a calculated osmolarity of at least 2,500 mOsm/L and formulated for sustained release, a kit for treating platinum-induced ototoxicity, and a method for enhancing the bioavailability of an anti-platinum chemoprotectant agent. These improvements enable more efficient and effective protection against ototoxicity.

The inventive concept's novelty lies in the specific combination of components and delivery methods that enhance the bioavailability and efficacy of the chemoprotectant agent. The inventive step is the recognition of the need for improved delivery and bioavailability, and the provision of solutions that address these limitations.

Alternative embodiments of the inventive concept may include different delivery devices, such as syringes or pumps, and various tonicity agents. The compositions may also be formulated for different routes of administration, such as intravenous or oral delivery.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the development of safer and more effective chemotherapy treatments. The target market includes pharmaceutical companies, hospitals, and research institutions focused on cancer treatment and ototoxicity prevention.